Survodtide (BI 456906) is an investigational dual agonist of and glucagon receptors developed by Boehringer Ingelheim. Unlike tirzeptid , survodtide combines GLP-1 with glucagon receptor activation, creating a distinct metabolic profile particularly studied for liver disease. The glucagon component drives hepatic fat oxidation and energy expenditure.
FOR RESEARCH USE ONLY. Not for human consumption. Not intended for human or veterinary use. For laboratory research and analytical purposes only.